MK-2461 (CAS: 917879-39-1) is a small-molecule inhibitor of c-Met, also known as hepatocyte growth factor receptor (HGFR), developed by Merck for the treatment of various cancers, such as non-small cell lung cancer and liver cancer. c-Met plays a critical role in tumor growth and metastasis.
Chemical name: 7-Ethyl-2-(4-fluorophenylamino)-4-oxo-3-quinolinecarboxamide
Molecular formula: C19H16FN3O2
Formula weight: 331.35 g/mol
CAS No: 917879-39-1
Top ten keywords from Google:
Synonyms:
Health benefits of this product: MK-2461 has shown potential in preclinical and clinical studies for the treatment of various cancers, particularly non-small cell lung cancer and liver cancer. It works by inhibiting the activity of c-Met, which is involved in tumor growth and metastasis. By blocking these receptors, MK-2461 can potentially induce apoptosis and inhibit tumor growth.
Potential effects: MK-2461 has demonstrated efficacy in reducing tumor growth and inducing remission in non-small cell lung cancer and liver cancer in preclinical and clinical studies. It has also shown potential in combination with other anti-cancer agents, such as chemotherapy and radiation therapy. However, more research is needed to determine its full potential and efficacy in different types of cancers.
Product mechanism: MK-2461 inhibits the activity of c-Met, also known as hepatocyte growth factor receptor (HGFR), which is involved in tumor growth and metastasis. Activation of this receptor by its ligand, hepatocyte growth factor (HGF), promotes cell proliferation, survival, and migration, leading to tumor growth and metastasis. As a small-molecule inhibitor, MK-2461 binds to the ATP-binding site of c-Met, preventing its activation and downstream signaling pathways that promote cancer cell growth and survival. By inhibiting these receptors, MK-2461 can induce apoptosis and inhibit tumor growth.
Safety: MK-2461 has been evaluated in several preclinical and clinical studies involving hundreds of patients with different types of cancers. Overall, it has been well-tolerated, with manageable side effects. The most common adverse events reported were fatigue, nausea, and diarrhea. More severe side effects, such as liver toxicity and neutropenia, were observed in some patients, but they were rare and usually resolved after dose adjustments or discontinuation.
Side effects: Common side effects of MK-2461 include fatigue, nausea, and diarrhea. These symptoms are usually mild or moderate and can be managed with supportive care or dose modifications. Less common but more severe side effects may include liver toxicity and neutropenia, which may require prompt medical intervention. Patients should be monitored closely for these adverse events and receive appropriate medical intervention if necessary.
Dosing information: The recommended dose of MK-2461 varies depending on the indication and the patient's condition. In clinical trials, doses ranging from 25 to 300 mg have been evaluated, either as a single agent or in combination with other drugs. Treatment duration also varies and can range from a few weeks to several months, depending on the response and tolerability. Patients should follow their doctor's instructions regarding dosing, administration, and monitoring.
Conclusion: MK-2461 (CAS: 917879-39-1) is a promising small-molecule inhibitor of c-Met, also known as hepatocyte growth factor receptor (HGFR), that has shown potential in preclinical and clinical studies for the treatment of various cancers, particularly non-small cell lung cancer and liver cancer. Its mechanism of action involves blocking key receptors involved in tumor growth and metastasis, leading to apoptosis and reduced tumor growth. Although it has been generally well-tolerated, it may cause some side effects that should be monitored closely. Further research is needed to determine its full potential and efficacy in different types of cancers.
